Alefacept

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Jan 1, 2008 → Oct 1, 2009

NCT ID

NCT00832585

About Alefacept

Alefacept is a approved stage product being developed by Astellas Pharma for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00832585. Target conditions include Atopic Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Dermatitis were approved

Approved (20) Terminated (1) Active (0)

✅LebrikizumabEli LillyApproved

✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved

✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved

✅tacrolimusAstellas PharmaApproved

✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved

✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved

✅Protopic + Corticosteroid + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01267643	Phase 1	Terminated	May 1, 2011	Apr 16, 2013	Aplastic Anemia
NCT01226420	Phase 2	Terminated	Oct 1, 2010	Aug 1, 2012	Chronic Graft-versus-host Disease
NCT00808223	Phase 2	Completed	Apr 1, 2009	Feb 1, 2012	Psoriasis
NCT00815633	Approved	Terminated	Dec 1, 2008	Mar 1, 2010	Pityriasis Rubra Pilaris
NCT00953329	Approved	Terminated	Feb 1, 2008	Dec 1, 2008	Chronic Plaque Psoriasis
NCT00832585	Approved	Completed	Jan 1, 2008	Oct 1, 2009	Atopic Dermatitis
NCT00658606	Approved	Completed	Oct 1, 2007	Dec 1, 2009	Plaque Psoriasis
NCT00168753	Approved	Completed	Jul 1, 2004	Mar 1, 2005	Moderate to Severe Chronic Plaque Psoriasis
NCT00674063	Phase 3	Completed	Jul 1, 2003	Apr 1, 2004	Chronic Plaque Psoriasis
NCT00692172	Phase 3	Completed	Dec 1, 2001	Nov 1, 2004	Psoriasis

Competing Products

20 competing products in Atopic Dermatitis

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab	Eli Lilly	Phase 3	40
Baricitinib + Placebo + Topical corticosteroid	Eli Lilly	Phase 3	40
Lebrikizumab	Eli Lilly	Approved	50
Lebrikizumab	Eli Lilly	Phase 3	40
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin	Hoth Therapeutics	Phase 1	19
Lebrikizumab	Eli Lilly	Phase 3	40
ASN008	Formation Bio	Phase 2	25
ENS-002	Concerto Biosciences	Phase 1	11
nemolizumab (CIM331)	Chugai Pharmaceutical	Phase 2	35
YH35324 + Placebo + Omalizumab	Yuhan	Phase 1	29
YH35324 + Placebo + Omalizumab	Yuhan	Phase 1	29
DS-2741a + Placebo	Daiichi Sankyo	Phase 1	21
SUN13834 + Placebo	Daiichi Sankyo	Phase 2	35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061	Daiichi Sankyo	Phase 2	35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%	Astellas Pharma	Phase 2	35
tacrolimus ointment	Astellas Pharma	Phase 3	40
tacrolimus 0.1% + fluticasone 0.005 %	Astellas Pharma	Approved	43
tacrolimus ointment + pimecrolimus cream	Astellas Pharma	Approved	43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAX	Astellas Pharma	Phase 2	35